Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-Lung12 adjuvant Dato-DXd and rilvegostomig in resected stage I adenocarcinoma NSCLC
jRCT2061240062Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2024
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) and Non-small cell lung cancer adenocarcinoma (NSCLC) comparing Dato-DXd in Combination With Rilvegostomig, Rilvegostomig Monotherapy and SoC: Observation Only or UFT (3 arms). Primary endpoint: Disease-free survival. Started Oct 2024; status: active, not recruiting.
02
Drugs
datopotamab deruxtecanrilvegostomigtegafur
03
Conditions
non-small cell lung cancer (NSCLC)Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on jRCT2061240062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061240062.